Skip to main content

Table 5 Best overall tumor response

From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Best overall response huKS-IL2 dosing cohort, mg/m2  
0.5 1.0 2.0 3.0 4.0 Overall
(n=3) (n=4) (n=6) (n=6) (n=7) (n=26)
n (%) n (%) n (%) n (%) n (%) n (%)
n (missing) 3 (0) 3 (1) 6 (0) 6 (0) 7 (0) 25 (1)
CR 0 0 0 0 0 0
PR 0 0 0 0 0 0
SD 1 (33.3) 1 (33.3) 2 (33.3) 3 (50.0) 3 (42.9) 10 (40.0)
PD 2 (66.7) 2 (66.7) 4 (66.7) 2 (33.3) 4 (57.1) 14 (56.0)
  1. Notes: Includes subjects who withdrew due to PD prior to an objective tumor response assessment. One subject discontinued the study due to treatment-emergent adverse events without any post-baseline disease assessment.
  2. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.